Loading stock data…
REGN
$701.42-5.64 (-0.80%)
Market ClosedLast close May 1
Regeneron Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regeneron Pharmaceuticals, Inc. in the Healthcare sector is trading at $701.42. The stock is currently 15% below its 52-week high of $821.11, remaining 2.8% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why REGN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$701.42
Potential Upside
15.9%
Whystock Fair Value$813.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$875.31+24.8%
Range$730.00 – $1057
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$78.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Strong income play. Yield provides a meaningful total return floor.
50.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.26%
Volume
Today's trading volume
728,877
Recent News
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says
Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales o
Regeneron Q1 2026 net income falls 10% to $727m
Regeneron’s total revenue increased 19% year-on-year to $3.6bn from $3.02bn.
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock.
Regeneron will face competition from new market entrants later this year, but upbeat data could change everything.
Regeneron Pharmaceuticals Q1 Earnings Call Highlights
Regeneron Pharmaceuticals (NASDAQ:REGN) reported what management described as a strong start to 2026, driven by growth in key commercial products, continued pipeline progress, and an updated capital return plan. On the company’s first-quarter earnings call, executives also addressed regulatory timin